Medical Care
Global Neuropathic Pain Therapeutics Market Research Report 2025
- Jul 08, 25
- ID: 347509
- Pages: 87
- Figures: 88
- Views: 1
The global market for Neuropathic Pain Therapeutics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Neuropathic pain therapeutics refers to a way to relieve and treat neuropathic pain through various drugs or treatments. Neuropathic pain is a chronic condition wherein pathological pain continues even after the cause of the pain is eliminated.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Neuropathic Pain Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuropathic Pain Therapeutics.
The Neuropathic Pain Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neuropathic Pain Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuropathic Pain Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Novartis AG
AstraZeneca
GlaxoSmithKline
Eli Lilly and Company
Mallinckrodt Pharmaceuticals
Johnson & Johnson
Abbott
Endo Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited
Merck & Co
Segment by Type
Anticonvulsants
Antidepressants
NSAIDs
Opioids
Steroids
Others
Segment by Application
Diabetic Neuropathy
Chemotherapy-Induced Neuropathy Pain
Postherpetic Neuralgia
Spinal Cord Injury
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuropathic Pain Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Neuropathic pain therapeutics refers to a way to relieve and treat neuropathic pain through various drugs or treatments. Neuropathic pain is a chronic condition wherein pathological pain continues even after the cause of the pain is eliminated.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Neuropathic Pain Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuropathic Pain Therapeutics.
The Neuropathic Pain Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neuropathic Pain Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuropathic Pain Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Novartis AG
AstraZeneca
GlaxoSmithKline
Eli Lilly and Company
Mallinckrodt Pharmaceuticals
Johnson & Johnson
Abbott
Endo Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited
Merck & Co
Segment by Type
Anticonvulsants
Antidepressants
NSAIDs
Opioids
Steroids
Others
Segment by Application
Diabetic Neuropathy
Chemotherapy-Induced Neuropathy Pain
Postherpetic Neuralgia
Spinal Cord Injury
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuropathic Pain Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuropathic Pain Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Anticonvulsants
1.2.3 Antidepressants
1.2.4 NSAIDs
1.2.5 Opioids
1.2.6 Steroids
1.2.7 Others
1.3 Market by Application
1.3.1 Global Neuropathic Pain Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Diabetic Neuropathy
1.3.3 Chemotherapy-Induced Neuropathy Pain
1.3.4 Postherpetic Neuralgia
1.3.5 Spinal Cord Injury
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neuropathic Pain Therapeutics Market Perspective (2020-2031)
2.2 Global Neuropathic Pain Therapeutics Growth Trends by Region
2.2.1 Global Neuropathic Pain Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Neuropathic Pain Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Neuropathic Pain Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Neuropathic Pain Therapeutics Market Dynamics
2.3.1 Neuropathic Pain Therapeutics Industry Trends
2.3.2 Neuropathic Pain Therapeutics Market Drivers
2.3.3 Neuropathic Pain Therapeutics Market Challenges
2.3.4 Neuropathic Pain Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neuropathic Pain Therapeutics Players by Revenue
3.1.1 Global Top Neuropathic Pain Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Neuropathic Pain Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Neuropathic Pain Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Neuropathic Pain Therapeutics Revenue
3.4 Global Neuropathic Pain Therapeutics Market Concentration Ratio
3.4.1 Global Neuropathic Pain Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuropathic Pain Therapeutics Revenue in 2024
3.5 Global Key Players of Neuropathic Pain Therapeutics Head office and Area Served
3.6 Global Key Players of Neuropathic Pain Therapeutics, Product and Application
3.7 Global Key Players of Neuropathic Pain Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuropathic Pain Therapeutics Breakdown Data by Type
4.1 Global Neuropathic Pain Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Neuropathic Pain Therapeutics Forecasted Market Size by Type (2026-2031)
5 Neuropathic Pain Therapeutics Breakdown Data by Application
5.1 Global Neuropathic Pain Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Neuropathic Pain Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Neuropathic Pain Therapeutics Market Size (2020-2031)
6.2 North America Neuropathic Pain Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Neuropathic Pain Therapeutics Market Size by Country (2020-2025)
6.4 North America Neuropathic Pain Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neuropathic Pain Therapeutics Market Size (2020-2031)
7.2 Europe Neuropathic Pain Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Neuropathic Pain Therapeutics Market Size by Country (2020-2025)
7.4 Europe Neuropathic Pain Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neuropathic Pain Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Neuropathic Pain Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Neuropathic Pain Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Neuropathic Pain Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neuropathic Pain Therapeutics Market Size (2020-2031)
9.2 Latin America Neuropathic Pain Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Neuropathic Pain Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Neuropathic Pain Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neuropathic Pain Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Neuropathic Pain Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Neuropathic Pain Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Neuropathic Pain Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Neuropathic Pain Therapeutics Introduction
11.1.4 Pfizer Revenue in Neuropathic Pain Therapeutics Business (2020-2025)
11.1.5 Pfizer Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Company Details
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG Neuropathic Pain Therapeutics Introduction
11.2.4 Novartis AG Revenue in Neuropathic Pain Therapeutics Business (2020-2025)
11.2.5 Novartis AG Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Details
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Neuropathic Pain Therapeutics Introduction
11.3.4 AstraZeneca Revenue in Neuropathic Pain Therapeutics Business (2020-2025)
11.3.5 AstraZeneca Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Details
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Neuropathic Pain Therapeutics Introduction
11.4.4 GlaxoSmithKline Revenue in Neuropathic Pain Therapeutics Business (2020-2025)
11.4.5 GlaxoSmithKline Recent Development
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Company Details
11.5.2 Eli Lilly and Company Business Overview
11.5.3 Eli Lilly and Company Neuropathic Pain Therapeutics Introduction
11.5.4 Eli Lilly and Company Revenue in Neuropathic Pain Therapeutics Business (2020-2025)
11.5.5 Eli Lilly and Company Recent Development
11.6 Mallinckrodt Pharmaceuticals
11.6.1 Mallinckrodt Pharmaceuticals Company Details
11.6.2 Mallinckrodt Pharmaceuticals Business Overview
11.6.3 Mallinckrodt Pharmaceuticals Neuropathic Pain Therapeutics Introduction
11.6.4 Mallinckrodt Pharmaceuticals Revenue in Neuropathic Pain Therapeutics Business (2020-2025)
11.6.5 Mallinckrodt Pharmaceuticals Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Details
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Neuropathic Pain Therapeutics Introduction
11.7.4 Johnson & Johnson Revenue in Neuropathic Pain Therapeutics Business (2020-2025)
11.7.5 Johnson & Johnson Recent Development
11.8 Abbott
11.8.1 Abbott Company Details
11.8.2 Abbott Business Overview
11.8.3 Abbott Neuropathic Pain Therapeutics Introduction
11.8.4 Abbott Revenue in Neuropathic Pain Therapeutics Business (2020-2025)
11.8.5 Abbott Recent Development
11.9 Endo Pharmaceuticals, Inc.
11.9.1 Endo Pharmaceuticals, Inc. Company Details
11.9.2 Endo Pharmaceuticals, Inc. Business Overview
11.9.3 Endo Pharmaceuticals, Inc. Neuropathic Pain Therapeutics Introduction
11.9.4 Endo Pharmaceuticals, Inc. Revenue in Neuropathic Pain Therapeutics Business (2020-2025)
11.9.5 Endo Pharmaceuticals, Inc. Recent Development
11.10 Teva Pharmaceutical Industries Limited
11.10.1 Teva Pharmaceutical Industries Limited Company Details
11.10.2 Teva Pharmaceutical Industries Limited Business Overview
11.10.3 Teva Pharmaceutical Industries Limited Neuropathic Pain Therapeutics Introduction
11.10.4 Teva Pharmaceutical Industries Limited Revenue in Neuropathic Pain Therapeutics Business (2020-2025)
11.10.5 Teva Pharmaceutical Industries Limited Recent Development
11.11 Merck & Co
11.11.1 Merck & Co Company Details
11.11.2 Merck & Co Business Overview
11.11.3 Merck & Co Neuropathic Pain Therapeutics Introduction
11.11.4 Merck & Co Revenue in Neuropathic Pain Therapeutics Business (2020-2025)
11.11.5 Merck & Co Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuropathic Pain Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Anticonvulsants
1.2.3 Antidepressants
1.2.4 NSAIDs
1.2.5 Opioids
1.2.6 Steroids
1.2.7 Others
1.3 Market by Application
1.3.1 Global Neuropathic Pain Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Diabetic Neuropathy
1.3.3 Chemotherapy-Induced Neuropathy Pain
1.3.4 Postherpetic Neuralgia
1.3.5 Spinal Cord Injury
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neuropathic Pain Therapeutics Market Perspective (2020-2031)
2.2 Global Neuropathic Pain Therapeutics Growth Trends by Region
2.2.1 Global Neuropathic Pain Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Neuropathic Pain Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Neuropathic Pain Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Neuropathic Pain Therapeutics Market Dynamics
2.3.1 Neuropathic Pain Therapeutics Industry Trends
2.3.2 Neuropathic Pain Therapeutics Market Drivers
2.3.3 Neuropathic Pain Therapeutics Market Challenges
2.3.4 Neuropathic Pain Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neuropathic Pain Therapeutics Players by Revenue
3.1.1 Global Top Neuropathic Pain Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Neuropathic Pain Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Neuropathic Pain Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Neuropathic Pain Therapeutics Revenue
3.4 Global Neuropathic Pain Therapeutics Market Concentration Ratio
3.4.1 Global Neuropathic Pain Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuropathic Pain Therapeutics Revenue in 2024
3.5 Global Key Players of Neuropathic Pain Therapeutics Head office and Area Served
3.6 Global Key Players of Neuropathic Pain Therapeutics, Product and Application
3.7 Global Key Players of Neuropathic Pain Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuropathic Pain Therapeutics Breakdown Data by Type
4.1 Global Neuropathic Pain Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Neuropathic Pain Therapeutics Forecasted Market Size by Type (2026-2031)
5 Neuropathic Pain Therapeutics Breakdown Data by Application
5.1 Global Neuropathic Pain Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Neuropathic Pain Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Neuropathic Pain Therapeutics Market Size (2020-2031)
6.2 North America Neuropathic Pain Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Neuropathic Pain Therapeutics Market Size by Country (2020-2025)
6.4 North America Neuropathic Pain Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neuropathic Pain Therapeutics Market Size (2020-2031)
7.2 Europe Neuropathic Pain Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Neuropathic Pain Therapeutics Market Size by Country (2020-2025)
7.4 Europe Neuropathic Pain Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neuropathic Pain Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Neuropathic Pain Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Neuropathic Pain Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Neuropathic Pain Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neuropathic Pain Therapeutics Market Size (2020-2031)
9.2 Latin America Neuropathic Pain Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Neuropathic Pain Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Neuropathic Pain Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neuropathic Pain Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Neuropathic Pain Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Neuropathic Pain Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Neuropathic Pain Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Neuropathic Pain Therapeutics Introduction
11.1.4 Pfizer Revenue in Neuropathic Pain Therapeutics Business (2020-2025)
11.1.5 Pfizer Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Company Details
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG Neuropathic Pain Therapeutics Introduction
11.2.4 Novartis AG Revenue in Neuropathic Pain Therapeutics Business (2020-2025)
11.2.5 Novartis AG Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Details
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Neuropathic Pain Therapeutics Introduction
11.3.4 AstraZeneca Revenue in Neuropathic Pain Therapeutics Business (2020-2025)
11.3.5 AstraZeneca Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Details
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Neuropathic Pain Therapeutics Introduction
11.4.4 GlaxoSmithKline Revenue in Neuropathic Pain Therapeutics Business (2020-2025)
11.4.5 GlaxoSmithKline Recent Development
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Company Details
11.5.2 Eli Lilly and Company Business Overview
11.5.3 Eli Lilly and Company Neuropathic Pain Therapeutics Introduction
11.5.4 Eli Lilly and Company Revenue in Neuropathic Pain Therapeutics Business (2020-2025)
11.5.5 Eli Lilly and Company Recent Development
11.6 Mallinckrodt Pharmaceuticals
11.6.1 Mallinckrodt Pharmaceuticals Company Details
11.6.2 Mallinckrodt Pharmaceuticals Business Overview
11.6.3 Mallinckrodt Pharmaceuticals Neuropathic Pain Therapeutics Introduction
11.6.4 Mallinckrodt Pharmaceuticals Revenue in Neuropathic Pain Therapeutics Business (2020-2025)
11.6.5 Mallinckrodt Pharmaceuticals Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Details
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Neuropathic Pain Therapeutics Introduction
11.7.4 Johnson & Johnson Revenue in Neuropathic Pain Therapeutics Business (2020-2025)
11.7.5 Johnson & Johnson Recent Development
11.8 Abbott
11.8.1 Abbott Company Details
11.8.2 Abbott Business Overview
11.8.3 Abbott Neuropathic Pain Therapeutics Introduction
11.8.4 Abbott Revenue in Neuropathic Pain Therapeutics Business (2020-2025)
11.8.5 Abbott Recent Development
11.9 Endo Pharmaceuticals, Inc.
11.9.1 Endo Pharmaceuticals, Inc. Company Details
11.9.2 Endo Pharmaceuticals, Inc. Business Overview
11.9.3 Endo Pharmaceuticals, Inc. Neuropathic Pain Therapeutics Introduction
11.9.4 Endo Pharmaceuticals, Inc. Revenue in Neuropathic Pain Therapeutics Business (2020-2025)
11.9.5 Endo Pharmaceuticals, Inc. Recent Development
11.10 Teva Pharmaceutical Industries Limited
11.10.1 Teva Pharmaceutical Industries Limited Company Details
11.10.2 Teva Pharmaceutical Industries Limited Business Overview
11.10.3 Teva Pharmaceutical Industries Limited Neuropathic Pain Therapeutics Introduction
11.10.4 Teva Pharmaceutical Industries Limited Revenue in Neuropathic Pain Therapeutics Business (2020-2025)
11.10.5 Teva Pharmaceutical Industries Limited Recent Development
11.11 Merck & Co
11.11.1 Merck & Co Company Details
11.11.2 Merck & Co Business Overview
11.11.3 Merck & Co Neuropathic Pain Therapeutics Introduction
11.11.4 Merck & Co Revenue in Neuropathic Pain Therapeutics Business (2020-2025)
11.11.5 Merck & Co Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Neuropathic Pain Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Anticonvulsants
Table 3. Key Players of Antidepressants
Table 4. Key Players of NSAIDs
Table 5. Key Players of Opioids
Table 6. Key Players of Steroids
Table 7. Key Players of Others
Table 8. Global Neuropathic Pain Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Neuropathic Pain Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Neuropathic Pain Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 11. Global Neuropathic Pain Therapeutics Market Share by Region (2020-2025)
Table 12. Global Neuropathic Pain Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 13. Global Neuropathic Pain Therapeutics Market Share by Region (2026-2031)
Table 14. Neuropathic Pain Therapeutics Market Trends
Table 15. Neuropathic Pain Therapeutics Market Drivers
Table 16. Neuropathic Pain Therapeutics Market Challenges
Table 17. Neuropathic Pain Therapeutics Market Restraints
Table 18. Global Neuropathic Pain Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Neuropathic Pain Therapeutics Market Share by Players (2020-2025)
Table 20. Global Top Neuropathic Pain Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuropathic Pain Therapeutics as of 2024)
Table 21. Ranking of Global Top Neuropathic Pain Therapeutics Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Neuropathic Pain Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Neuropathic Pain Therapeutics, Headquarters and Area Served
Table 24. Global Key Players of Neuropathic Pain Therapeutics, Product and Application
Table 25. Global Key Players of Neuropathic Pain Therapeutics, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Neuropathic Pain Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 28. Global Neuropathic Pain Therapeutics Revenue Market Share by Type (2020-2025)
Table 29. Global Neuropathic Pain Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 30. Global Neuropathic Pain Therapeutics Revenue Market Share by Type (2026-2031)
Table 31. Global Neuropathic Pain Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 32. Global Neuropathic Pain Therapeutics Revenue Market Share by Application (2020-2025)
Table 33. Global Neuropathic Pain Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 34. Global Neuropathic Pain Therapeutics Revenue Market Share by Application (2026-2031)
Table 35. North America Neuropathic Pain Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. North America Neuropathic Pain Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 37. North America Neuropathic Pain Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 38. Europe Neuropathic Pain Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 39. Europe Neuropathic Pain Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 40. Europe Neuropathic Pain Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 41. Asia-Pacific Neuropathic Pain Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 42. Asia-Pacific Neuropathic Pain Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 43. Asia-Pacific Neuropathic Pain Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 44. Latin America Neuropathic Pain Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Latin America Neuropathic Pain Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 46. Latin America Neuropathic Pain Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 47. Middle East & Africa Neuropathic Pain Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 48. Middle East & Africa Neuropathic Pain Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 49. Middle East & Africa Neuropathic Pain Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 50. Pfizer Company Details
Table 51. Pfizer Business Overview
Table 52. Pfizer Neuropathic Pain Therapeutics Product
Table 53. Pfizer Revenue in Neuropathic Pain Therapeutics Business (2020-2025) & (US$ Million)
Table 54. Pfizer Recent Development
Table 55. Novartis AG Company Details
Table 56. Novartis AG Business Overview
Table 57. Novartis AG Neuropathic Pain Therapeutics Product
Table 58. Novartis AG Revenue in Neuropathic Pain Therapeutics Business (2020-2025) & (US$ Million)
Table 59. Novartis AG Recent Development
Table 60. AstraZeneca Company Details
Table 61. AstraZeneca Business Overview
Table 62. AstraZeneca Neuropathic Pain Therapeutics Product
Table 63. AstraZeneca Revenue in Neuropathic Pain Therapeutics Business (2020-2025) & (US$ Million)
Table 64. AstraZeneca Recent Development
Table 65. GlaxoSmithKline Company Details
Table 66. GlaxoSmithKline Business Overview
Table 67. GlaxoSmithKline Neuropathic Pain Therapeutics Product
Table 68. GlaxoSmithKline Revenue in Neuropathic Pain Therapeutics Business (2020-2025) & (US$ Million)
Table 69. GlaxoSmithKline Recent Development
Table 70. Eli Lilly and Company Company Details
Table 71. Eli Lilly and Company Business Overview
Table 72. Eli Lilly and Company Neuropathic Pain Therapeutics Product
Table 73. Eli Lilly and Company Revenue in Neuropathic Pain Therapeutics Business (2020-2025) & (US$ Million)
Table 74. Eli Lilly and Company Recent Development
Table 75. Mallinckrodt Pharmaceuticals Company Details
Table 76. Mallinckrodt Pharmaceuticals Business Overview
Table 77. Mallinckrodt Pharmaceuticals Neuropathic Pain Therapeutics Product
Table 78. Mallinckrodt Pharmaceuticals Revenue in Neuropathic Pain Therapeutics Business (2020-2025) & (US$ Million)
Table 79. Mallinckrodt Pharmaceuticals Recent Development
Table 80. Johnson & Johnson Company Details
Table 81. Johnson & Johnson Business Overview
Table 82. Johnson & Johnson Neuropathic Pain Therapeutics Product
Table 83. Johnson & Johnson Revenue in Neuropathic Pain Therapeutics Business (2020-2025) & (US$ Million)
Table 84. Johnson & Johnson Recent Development
Table 85. Abbott Company Details
Table 86. Abbott Business Overview
Table 87. Abbott Neuropathic Pain Therapeutics Product
Table 88. Abbott Revenue in Neuropathic Pain Therapeutics Business (2020-2025) & (US$ Million)
Table 89. Abbott Recent Development
Table 90. Endo Pharmaceuticals, Inc. Company Details
Table 91. Endo Pharmaceuticals, Inc. Business Overview
Table 92. Endo Pharmaceuticals, Inc. Neuropathic Pain Therapeutics Product
Table 93. Endo Pharmaceuticals, Inc. Revenue in Neuropathic Pain Therapeutics Business (2020-2025) & (US$ Million)
Table 94. Endo Pharmaceuticals, Inc. Recent Development
Table 95. Teva Pharmaceutical Industries Limited Company Details
Table 96. Teva Pharmaceutical Industries Limited Business Overview
Table 97. Teva Pharmaceutical Industries Limited Neuropathic Pain Therapeutics Product
Table 98. Teva Pharmaceutical Industries Limited Revenue in Neuropathic Pain Therapeutics Business (2020-2025) & (US$ Million)
Table 99. Teva Pharmaceutical Industries Limited Recent Development
Table 100. Merck & Co Company Details
Table 101. Merck & Co Business Overview
Table 102. Merck & Co Neuropathic Pain Therapeutics Product
Table 103. Merck & Co Revenue in Neuropathic Pain Therapeutics Business (2020-2025) & (US$ Million)
Table 104. Merck & Co Recent Development
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
Table 108. Authors List of This Report
List of Figures
Figure 1. Neuropathic Pain Therapeutics Picture
Figure 2. Global Neuropathic Pain Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Neuropathic Pain Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Anticonvulsants Features
Figure 5. Antidepressants Features
Figure 6. NSAIDs Features
Figure 7. Opioids Features
Figure 8. Steroids Features
Figure 9. Others Features
Figure 10. Global Neuropathic Pain Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 11. Global Neuropathic Pain Therapeutics Market Share by Application: 2024 VS 2031
Figure 12. Diabetic Neuropathy Case Studies
Figure 13. Chemotherapy-Induced Neuropathy Pain Case Studies
Figure 14. Postherpetic Neuralgia Case Studies
Figure 15. Spinal Cord Injury Case Studies
Figure 16. Others Case Studies
Figure 17. Neuropathic Pain Therapeutics Report Years Considered
Figure 18. Global Neuropathic Pain Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 19. Global Neuropathic Pain Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 20. Global Neuropathic Pain Therapeutics Market Share by Region: 2024 VS 2031
Figure 21. Global Neuropathic Pain Therapeutics Market Share by Players in 2024
Figure 22. Global Top Neuropathic Pain Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuropathic Pain Therapeutics as of 2024)
Figure 23. The Top 10 and 5 Players Market Share by Neuropathic Pain Therapeutics Revenue in 2024
Figure 24. North America Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. North America Neuropathic Pain Therapeutics Market Share by Country (2020-2031)
Figure 26. United States Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Canada Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Europe Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Europe Neuropathic Pain Therapeutics Market Share by Country (2020-2031)
Figure 30. Germany Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. France Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. U.K. Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Italy Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Russia Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Nordic Countries Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Neuropathic Pain Therapeutics Market Share by Region (2020-2031)
Figure 38. China Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Japan Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. South Korea Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Southeast Asia Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. India Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Australia Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Latin America Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Latin America Neuropathic Pain Therapeutics Market Share by Country (2020-2031)
Figure 46. Mexico Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Brazil Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Middle East & Africa Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Middle East & Africa Neuropathic Pain Therapeutics Market Share by Country (2020-2031)
Figure 50. Turkey Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Saudi Arabia Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. UAE Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Pfizer Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2020-2025)
Figure 54. Novartis AG Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2020-2025)
Figure 55. AstraZeneca Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2020-2025)
Figure 56. GlaxoSmithKline Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2020-2025)
Figure 57. Eli Lilly and Company Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2020-2025)
Figure 58. Mallinckrodt Pharmaceuticals Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2020-2025)
Figure 59. Johnson & Johnson Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2020-2025)
Figure 60. Abbott Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2020-2025)
Figure 61. Endo Pharmaceuticals, Inc. Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2020-2025)
Figure 62. Teva Pharmaceutical Industries Limited Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2020-2025)
Figure 63. Merck & Co Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2020-2025)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Table 1. Global Neuropathic Pain Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Anticonvulsants
Table 3. Key Players of Antidepressants
Table 4. Key Players of NSAIDs
Table 5. Key Players of Opioids
Table 6. Key Players of Steroids
Table 7. Key Players of Others
Table 8. Global Neuropathic Pain Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Neuropathic Pain Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Neuropathic Pain Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 11. Global Neuropathic Pain Therapeutics Market Share by Region (2020-2025)
Table 12. Global Neuropathic Pain Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 13. Global Neuropathic Pain Therapeutics Market Share by Region (2026-2031)
Table 14. Neuropathic Pain Therapeutics Market Trends
Table 15. Neuropathic Pain Therapeutics Market Drivers
Table 16. Neuropathic Pain Therapeutics Market Challenges
Table 17. Neuropathic Pain Therapeutics Market Restraints
Table 18. Global Neuropathic Pain Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Neuropathic Pain Therapeutics Market Share by Players (2020-2025)
Table 20. Global Top Neuropathic Pain Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuropathic Pain Therapeutics as of 2024)
Table 21. Ranking of Global Top Neuropathic Pain Therapeutics Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Neuropathic Pain Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Neuropathic Pain Therapeutics, Headquarters and Area Served
Table 24. Global Key Players of Neuropathic Pain Therapeutics, Product and Application
Table 25. Global Key Players of Neuropathic Pain Therapeutics, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Neuropathic Pain Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 28. Global Neuropathic Pain Therapeutics Revenue Market Share by Type (2020-2025)
Table 29. Global Neuropathic Pain Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 30. Global Neuropathic Pain Therapeutics Revenue Market Share by Type (2026-2031)
Table 31. Global Neuropathic Pain Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 32. Global Neuropathic Pain Therapeutics Revenue Market Share by Application (2020-2025)
Table 33. Global Neuropathic Pain Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 34. Global Neuropathic Pain Therapeutics Revenue Market Share by Application (2026-2031)
Table 35. North America Neuropathic Pain Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. North America Neuropathic Pain Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 37. North America Neuropathic Pain Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 38. Europe Neuropathic Pain Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 39. Europe Neuropathic Pain Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 40. Europe Neuropathic Pain Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 41. Asia-Pacific Neuropathic Pain Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 42. Asia-Pacific Neuropathic Pain Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 43. Asia-Pacific Neuropathic Pain Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 44. Latin America Neuropathic Pain Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Latin America Neuropathic Pain Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 46. Latin America Neuropathic Pain Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 47. Middle East & Africa Neuropathic Pain Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 48. Middle East & Africa Neuropathic Pain Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 49. Middle East & Africa Neuropathic Pain Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 50. Pfizer Company Details
Table 51. Pfizer Business Overview
Table 52. Pfizer Neuropathic Pain Therapeutics Product
Table 53. Pfizer Revenue in Neuropathic Pain Therapeutics Business (2020-2025) & (US$ Million)
Table 54. Pfizer Recent Development
Table 55. Novartis AG Company Details
Table 56. Novartis AG Business Overview
Table 57. Novartis AG Neuropathic Pain Therapeutics Product
Table 58. Novartis AG Revenue in Neuropathic Pain Therapeutics Business (2020-2025) & (US$ Million)
Table 59. Novartis AG Recent Development
Table 60. AstraZeneca Company Details
Table 61. AstraZeneca Business Overview
Table 62. AstraZeneca Neuropathic Pain Therapeutics Product
Table 63. AstraZeneca Revenue in Neuropathic Pain Therapeutics Business (2020-2025) & (US$ Million)
Table 64. AstraZeneca Recent Development
Table 65. GlaxoSmithKline Company Details
Table 66. GlaxoSmithKline Business Overview
Table 67. GlaxoSmithKline Neuropathic Pain Therapeutics Product
Table 68. GlaxoSmithKline Revenue in Neuropathic Pain Therapeutics Business (2020-2025) & (US$ Million)
Table 69. GlaxoSmithKline Recent Development
Table 70. Eli Lilly and Company Company Details
Table 71. Eli Lilly and Company Business Overview
Table 72. Eli Lilly and Company Neuropathic Pain Therapeutics Product
Table 73. Eli Lilly and Company Revenue in Neuropathic Pain Therapeutics Business (2020-2025) & (US$ Million)
Table 74. Eli Lilly and Company Recent Development
Table 75. Mallinckrodt Pharmaceuticals Company Details
Table 76. Mallinckrodt Pharmaceuticals Business Overview
Table 77. Mallinckrodt Pharmaceuticals Neuropathic Pain Therapeutics Product
Table 78. Mallinckrodt Pharmaceuticals Revenue in Neuropathic Pain Therapeutics Business (2020-2025) & (US$ Million)
Table 79. Mallinckrodt Pharmaceuticals Recent Development
Table 80. Johnson & Johnson Company Details
Table 81. Johnson & Johnson Business Overview
Table 82. Johnson & Johnson Neuropathic Pain Therapeutics Product
Table 83. Johnson & Johnson Revenue in Neuropathic Pain Therapeutics Business (2020-2025) & (US$ Million)
Table 84. Johnson & Johnson Recent Development
Table 85. Abbott Company Details
Table 86. Abbott Business Overview
Table 87. Abbott Neuropathic Pain Therapeutics Product
Table 88. Abbott Revenue in Neuropathic Pain Therapeutics Business (2020-2025) & (US$ Million)
Table 89. Abbott Recent Development
Table 90. Endo Pharmaceuticals, Inc. Company Details
Table 91. Endo Pharmaceuticals, Inc. Business Overview
Table 92. Endo Pharmaceuticals, Inc. Neuropathic Pain Therapeutics Product
Table 93. Endo Pharmaceuticals, Inc. Revenue in Neuropathic Pain Therapeutics Business (2020-2025) & (US$ Million)
Table 94. Endo Pharmaceuticals, Inc. Recent Development
Table 95. Teva Pharmaceutical Industries Limited Company Details
Table 96. Teva Pharmaceutical Industries Limited Business Overview
Table 97. Teva Pharmaceutical Industries Limited Neuropathic Pain Therapeutics Product
Table 98. Teva Pharmaceutical Industries Limited Revenue in Neuropathic Pain Therapeutics Business (2020-2025) & (US$ Million)
Table 99. Teva Pharmaceutical Industries Limited Recent Development
Table 100. Merck & Co Company Details
Table 101. Merck & Co Business Overview
Table 102. Merck & Co Neuropathic Pain Therapeutics Product
Table 103. Merck & Co Revenue in Neuropathic Pain Therapeutics Business (2020-2025) & (US$ Million)
Table 104. Merck & Co Recent Development
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
Table 108. Authors List of This Report
List of Figures
Figure 1. Neuropathic Pain Therapeutics Picture
Figure 2. Global Neuropathic Pain Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Neuropathic Pain Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Anticonvulsants Features
Figure 5. Antidepressants Features
Figure 6. NSAIDs Features
Figure 7. Opioids Features
Figure 8. Steroids Features
Figure 9. Others Features
Figure 10. Global Neuropathic Pain Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 11. Global Neuropathic Pain Therapeutics Market Share by Application: 2024 VS 2031
Figure 12. Diabetic Neuropathy Case Studies
Figure 13. Chemotherapy-Induced Neuropathy Pain Case Studies
Figure 14. Postherpetic Neuralgia Case Studies
Figure 15. Spinal Cord Injury Case Studies
Figure 16. Others Case Studies
Figure 17. Neuropathic Pain Therapeutics Report Years Considered
Figure 18. Global Neuropathic Pain Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 19. Global Neuropathic Pain Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 20. Global Neuropathic Pain Therapeutics Market Share by Region: 2024 VS 2031
Figure 21. Global Neuropathic Pain Therapeutics Market Share by Players in 2024
Figure 22. Global Top Neuropathic Pain Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuropathic Pain Therapeutics as of 2024)
Figure 23. The Top 10 and 5 Players Market Share by Neuropathic Pain Therapeutics Revenue in 2024
Figure 24. North America Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. North America Neuropathic Pain Therapeutics Market Share by Country (2020-2031)
Figure 26. United States Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Canada Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Europe Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Europe Neuropathic Pain Therapeutics Market Share by Country (2020-2031)
Figure 30. Germany Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. France Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. U.K. Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Italy Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Russia Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Nordic Countries Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Neuropathic Pain Therapeutics Market Share by Region (2020-2031)
Figure 38. China Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Japan Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. South Korea Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Southeast Asia Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. India Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Australia Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Latin America Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Latin America Neuropathic Pain Therapeutics Market Share by Country (2020-2031)
Figure 46. Mexico Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Brazil Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Middle East & Africa Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Middle East & Africa Neuropathic Pain Therapeutics Market Share by Country (2020-2031)
Figure 50. Turkey Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Saudi Arabia Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. UAE Neuropathic Pain Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Pfizer Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2020-2025)
Figure 54. Novartis AG Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2020-2025)
Figure 55. AstraZeneca Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2020-2025)
Figure 56. GlaxoSmithKline Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2020-2025)
Figure 57. Eli Lilly and Company Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2020-2025)
Figure 58. Mallinckrodt Pharmaceuticals Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2020-2025)
Figure 59. Johnson & Johnson Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2020-2025)
Figure 60. Abbott Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2020-2025)
Figure 61. Endo Pharmaceuticals, Inc. Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2020-2025)
Figure 62. Teva Pharmaceutical Industries Limited Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2020-2025)
Figure 63. Merck & Co Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2020-2025)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Electrolytes for Lithium-Ion Batteries Market Research Report 2025
Jul 14, 25
Global Vanadium Products Market Research Report 2025
Jul 14, 25
Global High-purity Vanadium Oxide Market Research Report 2025
Jul 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232